JP2005510253A - ヒトＩｇλ軽鎖遺伝子を保有するトランスジェニック動物 - Google Patents

ヒトＩｇλ軽鎖遺伝子を保有するトランスジェニック動物 Download PDF

Info

Publication number
JP2005510253A
JP2005510253A JP2003548609A JP2003548609A JP2005510253A JP 2005510253 A JP2005510253 A JP 2005510253A JP 2003548609 A JP2003548609 A JP 2003548609A JP 2003548609 A JP2003548609 A JP 2003548609A JP 2005510253 A JP2005510253 A JP 2005510253A
Authority
JP
Japan
Prior art keywords
human
cell
light chain
transgenic animal
chain locus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003548609A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005510253A5 (enExample
Inventor
ラリー エル． グリーン，
ブラディミアー イバノブ，
Original Assignee
アブジェニックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23307544&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2005510253(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アブジェニックス インコーポレイテッド filed Critical アブジェニックス インコーポレイテッド
Publication of JP2005510253A publication Critical patent/JP2005510253A/ja
Publication of JP2005510253A5 publication Critical patent/JP2005510253A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/206—Pseudochromosomes, minichrosomosomes of yeast origin, e.g. YAC, 2u

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2003548609A 2001-11-30 2002-11-27 ヒトＩｇλ軽鎖遺伝子を保有するトランスジェニック動物 Pending JP2005510253A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33450801P 2001-11-30 2001-11-30
PCT/US2002/038245 WO2003047336A2 (en) 2001-11-30 2002-11-27 TRANSGENIC ANIMALS BEARING HUMAN Igμ LIGHT CHAIN GENES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009018855A Division JP2009100765A (ja) 2001-11-30 2009-01-29 ヒトＩｇλ軽鎖遺伝子を保有するトランスジェニック動物

Publications (2)

Publication Number Publication Date
JP2005510253A true JP2005510253A (ja) 2005-04-21
JP2005510253A5 JP2005510253A5 (enExample) 2005-12-22

Family

ID=23307544

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2003548609A Pending JP2005510253A (ja) 2001-11-30 2002-11-27 ヒトＩｇλ軽鎖遺伝子を保有するトランスジェニック動物
JP2009018855A Withdrawn JP2009100765A (ja) 2001-11-30 2009-01-29 ヒトＩｇλ軽鎖遺伝子を保有するトランスジェニック動物
JP2010023628A Pending JP2010136726A (ja) 2001-11-30 2010-02-04 ヒトＩｇλ軽鎖遺伝子を保有するトランスジェニック動物
JP2013097307A Pending JP2013198489A (ja) 2001-11-30 2013-05-07 ヒトＩｇλ軽鎖遺伝子を保有するトランスジェニック動物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2009018855A Withdrawn JP2009100765A (ja) 2001-11-30 2009-01-29 ヒトＩｇλ軽鎖遺伝子を保有するトランスジェニック動物
JP2010023628A Pending JP2010136726A (ja) 2001-11-30 2010-02-04 ヒトＩｇλ軽鎖遺伝子を保有するトランスジェニック動物
JP2013097307A Pending JP2013198489A (ja) 2001-11-30 2013-05-07 ヒトＩｇλ軽鎖遺伝子を保有するトランスジェニック動物

Country Status (8)

Country Link
US (1) US7435871B2 (enExample)
EP (4) EP1461442B1 (enExample)
JP (4) JP2005510253A (enExample)
AU (1) AU2002348263B2 (enExample)
CA (2) CA2468565C (enExample)
DK (2) DK2319301T3 (enExample)
ES (2) ES2645563T3 (enExample)
WO (1) WO2003047336A2 (enExample)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013532974A (ja) * 2010-06-22 2013-08-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトλ可変領域およびマウス定常領域を含む軽鎖を発現するマウス
JP2014531452A (ja) * 2011-09-19 2014-11-27 カイマブ・リミテッド 動物、レパートリーおよび方法
JP2015512634A (ja) * 2012-03-28 2015-04-30 カイマブ・リミテッド 動物モデルおよび治療用分子
JP2016534751A (ja) * 2013-10-01 2016-11-10 カイマブ・リミテッド 動物モデル及び治療用分子
US9963716B2 (en) 2011-09-26 2018-05-08 Kymab Limited Chimaeric surrogate light chains (SLC) comprising human VpreB
US10064398B2 (en) 2009-07-08 2018-09-04 Kymab Limited Animal models and therapeutic molecules
US10667501B2 (en) 2012-05-17 2020-06-02 Kymab Limited Transgenic non-human vertebrate for the in vivo production of dual specificity immunoglobulins or hypermutated heavy chain only immunoglobulins
JP2020110187A (ja) * 2012-06-12 2020-07-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 限定された免疫グロブリン重鎖遺伝子座を有するヒト化非ヒト動物
US11051497B2 (en) 2011-09-19 2021-07-06 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
JP2021536478A (ja) * 2018-09-06 2021-12-27 カイマブ・リミテッド 対合していない可変ドメインを含む抗原結合分子
US11612151B2 (en) 2011-12-20 2023-03-28 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US11820810B2 (en) 2013-05-02 2023-11-21 Kymab Limited Antibodies, variable domains and chains tailored for human use

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
US8541008B2 (en) * 1999-11-19 2013-09-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against candidiasis
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
DK1354034T3 (da) 2000-11-30 2008-03-25 Medarex Inc Transgene transchromosomale gnavere til fremstilling af humane antistoffer
DE60227067D1 (de) * 2001-05-11 2008-07-24 Kirin Pharma Kk Künstliches menschliches chromosom mit dem gen für die lambda-leichte kette menschlicher antikörper
EP2395017A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
KR101531400B1 (ko) 2003-06-27 2015-06-26 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그용도
WO2005092926A2 (en) 2004-03-19 2005-10-06 Amgen Inc. Reducing the risk of human and anti-human antibodies through v gene manipulation
US7625549B2 (en) 2004-03-19 2009-12-01 Amgen Fremont Inc. Determining the risk of human anti-human antibodies in transgenic mice
US20080026457A1 (en) 2004-10-22 2008-01-31 Kevin Wells Ungulates with genetically modified immune systems
ES2679282T3 (es) * 2004-10-22 2018-08-23 Revivicor Inc. Porcinos transgénicos que carecen de cadena ligera de inmunoglobulina endógena
EP1851245B1 (en) 2005-01-26 2012-10-10 Amgen Fremont Inc. Antibodies against interleukin-1 beta
WO2006113643A2 (en) 2005-04-20 2006-10-26 Amgen Fremont Inc. High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies
WO2006117699A2 (en) * 2005-04-29 2006-11-09 Innate Pharma Transgenic animals and methods of making recombinant antibodies
NL1029605C2 (nl) * 2005-07-25 2007-01-26 Li-Te Chin Nieuwe uit menselijke kiemlijnsequenties gewonnen antilichaamstructuren.
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
EP2167669A2 (en) 2007-05-31 2010-03-31 Genmab A/S Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals
EP2602323B1 (en) 2007-06-01 2018-02-28 Open Monoclonal Technology, Inc. Compositions and methods for inhibiting endogenous immunoglobin genes and producing transgenic human idiotype antibodies
LT2346994T (lt) 2008-09-30 2022-03-10 Ablexis, Llc Knock-in pelė, skirta chimerinių antikūnų gamybai
DK2348827T3 (en) 2008-10-27 2015-07-20 Revivicor Inc IMMUNICIPLY COMPROMATED PETS
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
NO2719708T3 (enExample) 2009-11-13 2018-03-24
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
SMT201900372T1 (it) 2010-02-08 2019-09-09 Regeneron Pharma Topo con catena leggera comune
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20120021409A1 (en) * 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
KR102004106B1 (ko) 2010-03-31 2019-07-25 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
RU2612903C2 (ru) * 2010-08-02 2017-03-13 Ридженерон Фармасьютикалз, Инк. Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены
JP2013540694A (ja) 2010-08-06 2013-11-07 ウー３・フアルマ・ゲー・エム・ベー・ハー Ｈｅｒ３結合剤の前立腺治療における使用
TWI636993B (zh) 2010-10-27 2018-10-01 安美基公司 Ｄｋｋ１抗體及使用方法
EP2704743B1 (en) * 2011-05-04 2020-03-11 Omeros Corporation Compositions for inhibiting masp-2 dependent complement acitivation
CN103998056B (zh) 2011-07-22 2017-09-12 诺瓦蒂格姆疗法有限公司 用于接种抗金黄色葡萄球菌疫苗的方法和组合物
HUE068728T2 (hu) 2011-08-05 2025-01-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
IN2014CN02113A (enExample) 2011-09-21 2015-05-29 Fujirebio Kk
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
PE20141937A1 (es) 2011-11-16 2014-12-18 Amgen Inc Metodos para tratar trastornos relacionados con mutante viii de eliminacion de factor de crecimiento epidermico
KR102213535B1 (ko) 2012-03-16 2021-02-08 리제너론 파마슈티칼스 인코포레이티드 pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물
EP3348140B1 (en) 2012-03-16 2020-12-30 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
CA2865644A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
JP5976380B2 (ja) 2012-04-27 2016-08-23 公益財団法人東京都医学総合研究所 ウロキナーゼ型プラスミノーゲンアクチベータートランスジェニックマウス
ES2728936T3 (es) 2013-01-25 2019-10-29 Amgen Inc Anticuerpos dirigidos contra CDH19 para melanoma
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
RS57582B1 (sr) * 2013-02-20 2018-11-30 Regeneron Pharma Nehumane životinje sa modifikovanim sekvencama imunoglobulinskog teškog lanca
US20160122436A1 (en) 2013-03-15 2016-05-05 Amgen Research (Munich) Gmbh Single chain binding molecules comprising n-terminal abp
EA030005B1 (ru) 2013-03-15 2018-06-29 Лос-Анджелес Биомедикал Ресерч Институт Эт Харбор-Укла Медикал Центер Композиции и способы лечения грибковых и бактериальных патогенов
EP2970446A1 (en) 2013-03-15 2016-01-20 Amgen Research (Munich) GmbH Antibody constructs for influenza m2 and cd3
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
WO2015143406A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
RU2016141307A (ru) 2014-03-21 2018-04-24 Регенерон Фармасьютикалз, Инк. Отличные от человека животные, которые вырабатывают однодоменные связывающие белки
AR101400A1 (es) 2014-07-31 2016-12-14 Amgen Res Munich Gmbh Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido
CA2956471C (en) 2014-07-31 2024-09-10 Amgen Res Munich Gmbh OPTIMIZED CONSTRUCTIONS OF SINGLE-CATENAL, BI-SPECIFIC, AND CROSS-SPECIFIC ANTIBODY
AR101669A1 (es) 2014-07-31 2017-01-04 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
AU2016250023B2 (en) 2015-04-17 2022-02-24 Amgen Research (Munich) Gmbh Bispecific antibody constructs for CDH3 and CD3
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
PT3411402T (pt) 2016-02-03 2022-02-01 Amgen Inc Construtos de anticorpos biespecíficos engajadores de células t contra bcma e cd3
LT3411404T (lt) 2016-02-03 2022-12-27 Amgen Research (Munich) Gmbh Psma ir cd3 bispecifiniai, t ląsteles aktyvuojantys antikūno konstruktai
CN108883167A (zh) 2016-03-09 2018-11-23 加州大学洛杉矶分校港口医学中心生物医学研究所 用于预防和治疗外阴阴道念珠菌病的方法和药剂盒
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
WO2017214089A1 (en) 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
MA53935A (fr) 2016-11-04 2021-12-22 Regeneron Pharma Animaux non humains ayant un locus à chaîne légère lambda d'immunoglobuline modifiée
SG10202109874VA (en) 2017-01-19 2021-10-28 Open Monoclonal Tech Inc Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
SG11201909547TA (en) 2017-05-05 2019-11-28 Amgen Inc Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
PL3720279T3 (pl) 2017-12-05 2023-01-16 Regeneron Pharmaceuticals, Inc. Myszy posiadające zmodyfikowany sposobami inżynierii łańcuch lekki lambda immunoglobuliny oraz ich zastosowania
IL321479A (en) 2017-12-11 2025-08-01 Amgen Inc Lengthy manufacturing process for bispecific antibody products
TW201940518A (zh) 2017-12-29 2019-10-16 美商安進公司 針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體
CN112771075A (zh) 2018-07-30 2021-05-07 安进研发（慕尼黑）股份有限公司 结合至cd33和cd3的双特异性抗体构建体的延长施用
CN112512581B (zh) 2018-08-03 2024-12-17 安进研发（慕尼黑）股份有限公司 针对cldn18.2和cd3的抗体构建体
KR20210052494A (ko) 2018-08-27 2021-05-10 아피메트 게엠베하 항체 구조물이 사전 로드된 동결 보존된 nk 세포
MX2021003976A (es) 2018-10-11 2021-05-27 Amgen Inc Procesamiento posterior de constructos de anticuerpos biespecificos.
CA3136478A1 (en) 2019-06-05 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
TWI874409B (zh) 2019-06-13 2025-03-01 美商安進公司 生物製品製造中基於生物量之自動灌注控制
AU2020345787A1 (en) 2019-09-10 2022-03-24 Amgen Inc. Purification method for bispecific antigen-binding polypeptides with enhanced protein L capture dynamic binding capacity
EP4058485A1 (en) 2019-11-13 2022-09-21 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
US11926672B2 (en) 2019-12-20 2024-03-12 Amgen Inc. Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors
WO2021130383A1 (en) 2019-12-27 2021-07-01 Affimed Gmbh Method for the production of bispecific fcyriii x cd30 antibody construct
US20230093169A1 (en) 2020-01-22 2023-03-23 Amgen Research (Munch) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
WO2021183861A1 (en) 2020-03-12 2021-09-16 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
CA3175275A1 (en) 2020-03-19 2021-09-23 Amgen Inc. Antibodies against mucin 17 and uses thereof
JP2023527293A (ja) 2020-05-19 2023-06-28 アムジエン・インコーポレーテツド Ｍａｇｅｂ２結合構築物
CA3183693A1 (en) 2020-05-29 2021-12-02 Amgen Inc. Adverse effects-mitigating administration of a bispecific construct binding to cd33 and cd3
CA3187272A1 (en) 2020-10-08 2022-04-14 Thorsten Ross Trispecific binders
CA3198064A1 (en) 2020-11-06 2022-05-12 Amgen Inc. Antigen binding domain with reduced clipping rate
EP4240767A1 (en) 2020-11-06 2023-09-13 Amgen Inc. Polypeptide constructs binding to cd3
CR20230229A (es) 2020-11-06 2023-09-05 Amgen Res Munich Gmbh Moléculas de unión a antígeno biespecíficas con múltiples dianas de selectividad aumentada
CR20230235A (es) 2020-11-06 2023-10-05 Amgen Res Munich Gmbh Construcciones polipeptídicas que se unen selectivamente a cldn6 y cd3
CA3205586A1 (en) 2020-12-16 2022-06-23 Voyager Therapeutics, Inc. Tau binding compounds
AR125290A1 (es) 2021-04-02 2023-07-05 Amgen Inc Construcciones de unión a mageb2
US20240384006A1 (en) 2021-05-06 2024-11-21 Amgen Research (Munich) Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
EP4376958A1 (en) 2021-07-30 2024-06-05 Affimed GmbH Duplexbodies
AU2022381918A1 (en) 2021-11-03 2024-06-13 Affimed Gmbh Bispecific cd16a binders
TW202334221A (zh) 2021-11-03 2023-09-01 德商安富美德有限公司 雙特異性cd16a結合劑
IL316597A (en) 2022-05-12 2024-12-01 Amgen Res Munich Gmbh Multi-chain, multi-purpose, bispecific antigen-binding compounds with enhanced sensitivity
EP4543473A1 (en) 2022-06-22 2025-04-30 Voyager Therapeutics, Inc. Tau binding compounds
WO2024059675A2 (en) 2022-09-14 2024-03-21 Amgen Inc. Bispecific molecule stabilizing composition
TW202510911A (zh) 2023-06-14 2025-03-16 美商安進公司 Ｔ細胞接合劑掩蔽分子

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) * 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
FR2664073A1 (fr) 1990-06-29 1992-01-03 Thomson Csf Moyens de marquage d'objets, procede de realisation et dispositif de lecture.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) * 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) * 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5789650A (en) * 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
WO1992004893A1 (en) 1990-09-13 1992-04-02 Smithkline Beecham Corporation Non-aqueous liquid oral suspensions
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
KR19980701536A (ko) 1995-01-20 1998-05-15 케더린 세레다 글라우브 융합된 세포에서 스크린 효과를 개선시키는 방법
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
DE69738539T2 (de) * 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
TWI255853B (en) * 1998-08-21 2006-06-01 Kirin Brewery Method for modifying chromosomes
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US6833268B1 (en) * 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US7074983B2 (en) * 1999-11-19 2006-07-11 Kirin Beer Kabushiki Kaisha Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60227067D1 (de) 2001-05-11 2008-07-24 Kirin Pharma Kk Künstliches menschliches chromosom mit dem gen für die lambda-leichte kette menschlicher antikörper
JP6071725B2 (ja) 2013-04-23 2017-02-01 カルソニックカンセイ株式会社 電気自動車の駆動力制御装置

Cited By (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10064398B2 (en) 2009-07-08 2018-09-04 Kymab Limited Animal models and therapeutic molecules
US11812731B2 (en) 2009-07-08 2023-11-14 Kymab Ltd. Animal models and therapeutic molecules
US11606941B2 (en) 2009-07-08 2023-03-21 Kymab Limited Animal models and therapeutic molecules
US11564380B2 (en) 2009-07-08 2023-01-31 Kymab Limited Animal models and therapeutic molecules
US10165763B2 (en) 2009-07-08 2019-01-01 Kymab Limited Animal models and therapeutic molecules
JP2020128440A (ja) * 2010-06-22 2020-08-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒトλ可変領域およびマウス定常領域を含む軽鎖を発現するマウス
KR20190142436A (ko) * 2010-06-22 2019-12-26 리제너론 파아마슈티컬스, 인크. 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
JP2018023403A (ja) * 2010-06-22 2018-02-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ハイブリッド軽鎖マウス
JP2022066449A (ja) * 2010-06-22 2022-04-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ハイブリッド軽鎖マウス
KR102193823B1 (ko) 2010-06-22 2020-12-22 리제너론 파아마슈티컬스, 인크. 하이브리드 경쇄 마우스
JP2017006152A (ja) * 2010-06-22 2017-01-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒトλ可変領域およびマウス定常領域を含む軽鎖を発現するマウス
JP2016010415A (ja) * 2010-06-22 2016-01-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒトλ可変領域およびマウス定常領域を含む軽鎖を発現するマウス
KR20180135996A (ko) * 2010-06-22 2018-12-21 리제너론 파아마슈티컬스, 인크. 하이브리드 경쇄 마우스
KR20180135997A (ko) * 2010-06-22 2018-12-21 리제너론 파아마슈티컬스, 인크. 하이브리드 경쇄 마우스
JP2018201527A (ja) * 2010-06-22 2018-12-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒトλ可変領域およびマウス定常領域を含む軽鎖を発現するマウス
KR20210134424A (ko) * 2010-06-22 2021-11-09 리제너론 파아마슈티컬스, 인크. 하이브리드 경쇄 마우스
KR101934852B1 (ko) 2010-06-22 2019-01-04 리제너론 파아마슈티컬스, 인크. 하이브리드 경쇄 마우스
KR101945352B1 (ko) 2010-06-22 2019-02-07 리제너론 파아마슈티컬스, 인크. 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR20190014578A (ko) * 2010-06-22 2019-02-12 리제너론 파아마슈티컬스, 인크. 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR20190014576A (ko) * 2010-06-22 2019-02-12 리제너론 파아마슈티컬스, 인크. 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR101970944B1 (ko) 2010-06-22 2019-04-23 리제너론 파아마슈티컬스, 인크. 하이브리드 경쇄 마우스
KR20190049932A (ko) * 2010-06-22 2019-05-09 리제너론 파아마슈티컬스, 인크. 하이브리드 경쇄 마우스
KR101975884B1 (ko) 2010-06-22 2019-05-10 리제너론 파아마슈티컬스, 인크. 하이브리드 경쇄 마우스
KR101991234B1 (ko) 2010-06-22 2019-06-20 리제너론 파아마슈티컬스, 인크. 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR20190073584A (ko) * 2010-06-22 2019-06-26 리제너론 파아마슈티컬스, 인크. 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR102001430B1 (ko) 2010-06-22 2019-07-18 리제너론 파아마슈티컬스, 인크. 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR102462042B1 (ko) 2010-06-22 2022-11-03 리제너론 파아마슈티컬스, 인크. 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR102059909B1 (ko) 2010-06-22 2019-12-27 리제너론 파아마슈티컬스, 인크. 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR102320944B1 (ko) 2010-06-22 2021-11-04 리제너론 파아마슈티컬스, 인크. 하이브리드 경쇄 마우스
KR20210073609A (ko) * 2010-06-22 2021-06-18 리제너론 파아마슈티컬스, 인크. 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR102118565B1 (ko) 2010-06-22 2020-06-03 리제너론 파아마슈티컬스, 인크. 하이브리드 경쇄 마우스
KR20200064166A (ko) * 2010-06-22 2020-06-05 리제너론 파아마슈티컬스, 인크. 하이브리드 경쇄 마우스
JP7236409B2 (ja) 2010-06-22 2023-03-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトλ可変領域およびマウス定常領域を含む軽鎖を発現するマウス
KR102266097B1 (ko) 2010-06-22 2021-06-18 리제너론 파아마슈티컬스, 인크. 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR102506001B1 (ko) 2010-06-22 2023-03-07 리제너론 파아마슈티컬스, 인크. 하이브리드 경쇄 마우스
JP2013532974A (ja) * 2010-06-22 2013-08-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトλ可変領域およびマウス定常領域を含む軽鎖を発現するマウス
KR20200143511A (ko) * 2010-06-22 2020-12-23 리제너론 파아마슈티컬스, 인크. 하이브리드 경쇄 마우스
KR20210013376A (ko) * 2010-06-22 2021-02-03 리제너론 파아마슈티컬스, 인크. 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR102211911B1 (ko) 2010-06-22 2021-02-05 리제너론 파아마슈티컬스, 인크. 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
JP2017213005A (ja) * 2011-09-19 2017-12-07 カイマブ・リミテッド 動物、レパートリーおよび方法
US11051497B2 (en) 2011-09-19 2021-07-06 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
JP2014531452A (ja) * 2011-09-19 2014-11-27 カイマブ・リミテッド 動物、レパートリーおよび方法
US9963716B2 (en) 2011-09-26 2018-05-08 Kymab Limited Chimaeric surrogate light chains (SLC) comprising human VpreB
US11612151B2 (en) 2011-12-20 2023-03-28 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
US11617357B2 (en) 2011-12-20 2023-04-04 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
US12433266B2 (en) 2011-12-20 2025-10-07 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
JP2018119012A (ja) * 2012-03-28 2018-08-02 カイマブ・リミテッド 動物モデルおよび治療用分子
JP2020176140A (ja) * 2012-03-28 2020-10-29 カイマブ・リミテッド 動物モデルおよび治療用分子
JP7475415B2 (ja) 2012-03-28 2024-04-26 カイマブ・リミテッド 動物モデルおよび治療用分子
JP2023009136A (ja) * 2012-03-28 2023-01-19 カイマブ・リミテッド 動物モデルおよび治療用分子
JP2015512634A (ja) * 2012-03-28 2015-04-30 カイマブ・リミテッド 動物モデルおよび治療用分子
US10667501B2 (en) 2012-05-17 2020-06-02 Kymab Limited Transgenic non-human vertebrate for the in vivo production of dual specificity immunoglobulins or hypermutated heavy chain only immunoglobulins
US11559050B2 (en) 2012-06-12 2023-01-24 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci
JP2020110187A (ja) * 2012-06-12 2020-07-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 限定された免疫グロブリン重鎖遺伝子座を有するヒト化非ヒト動物
JP7106596B2 (ja) 2012-06-12 2022-07-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 限定された免疫グロブリン重鎖遺伝子座を有するヒト化非ヒト動物
JP2022090103A (ja) * 2012-06-12 2022-06-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 限定された免疫グロブリン重鎖遺伝子座を有するヒト化非ヒト動物
US11666040B2 (en) 2012-06-12 2023-06-06 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US11820810B2 (en) 2013-05-02 2023-11-21 Kymab Limited Antibodies, variable domains and chains tailored for human use
JP2020036618A (ja) * 2013-10-01 2020-03-12 カイマブ・リミテッド 動物モデル及び治療用分子
JP2016534751A (ja) * 2013-10-01 2016-11-10 カイマブ・リミテッド 動物モデル及び治療用分子
US11399522B2 (en) 2013-10-01 2022-08-02 Kymab Limited Animal models and therapeutic molecules
US10149462B2 (en) 2013-10-01 2018-12-11 Kymab Limited Animal models and therapeutic molecules
JP2021536478A (ja) * 2018-09-06 2021-12-27 カイマブ・リミテッド 対合していない可変ドメインを含む抗原結合分子
JP2024177226A (ja) * 2018-09-06 2024-12-19 カイマブ・リミテッド 対合していない可変ドメインを含む抗原結合分子

Also Published As

Publication number Publication date
CA2468565C (en) 2014-06-03
AU2002348263A1 (en) 2003-06-17
EP1461442B1 (en) 2017-09-06
US7435871B2 (en) 2008-10-14
WO2003047336A2 (en) 2003-06-12
CA2468565A1 (en) 2003-06-12
JP2013198489A (ja) 2013-10-03
JP2009100765A (ja) 2009-05-14
EP3698626A1 (en) 2020-08-26
JP2010136726A (ja) 2010-06-24
EP1461442A4 (en) 2006-11-29
EP2319301A2 (en) 2011-05-11
HK1248985A1 (en) 2018-10-26
DK1461442T3 (en) 2017-12-04
ES2645563T3 (es) 2017-12-05
EP2319301A3 (en) 2011-06-29
DK2319301T3 (en) 2017-12-04
WO2003047336A3 (en) 2004-06-24
ES2645698T3 (es) 2017-12-07
EP3269235B1 (en) 2022-01-26
CA2847885C (en) 2022-03-22
US20030217373A1 (en) 2003-11-20
CA2847885A1 (en) 2003-06-12
EP1461442A2 (en) 2004-09-29
AU2002348263B2 (en) 2008-10-16
EP3269235A1 (en) 2018-01-17
EP2319301B1 (en) 2017-09-06

Similar Documents

Publication Publication Date Title
US7435871B2 (en) Transgenic animals bearing human Igλ light chain genes
RU2761639C2 (ru) Мыши с гуманизированной легкой цепью
JP3523245B1 (ja) ヒト抗体作製用トランスジェニック染色体導入齧歯動物
US8809051B2 (en) Transgenic mammals having human Ig loci including plural VH and Vκ regions and antibodies produced therefrom
NZ727084A (en) Humanized universal light chain mice
SG192933A1 (en) Adam6 mice
HK40035928A (en) Transgenic animals bearing human ig lambda light chain genes
HK1248985B (en) Transgenic mice bearing human ig lambda light chain genes
RU2787781C2 (ru) Мыши с гуманизированной универсальной легкой цепью
HK1157135A (en) Transgenic animals bearing human ig lambda light chain genes
HK1202772B (en) Humanized light chain mice
NZ627211B2 (en) Humanized light chain mice

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081014

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081021

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081126

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081222

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090129

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090804